City of Hope Academic Research melanoma

Expanding the Reach of TIL Therapy: What Will it Take?

by Monty Pal
· Amaze Media Labs

Aug 4^th 2025
38 mins
On the Edge of Breakthrough: Voices of Cancer Research

Share This Article

Clips

Summary

Dr. Mahuron shares how tumor-infiltrating lymphocyte (TIL) therapy is evolving to reach more patients and improve cancer outcomes.

What does it take to bring tumor-infiltrating lymphocyte (TIL) therapy to more patients and make the therapy more effective for those already eligible?

In this episode of Edge of Breakthrough, Dr. Monty Pal sits down with Dr. Kelly Mahuron, a surgical oncologist at City of Hope, to unpack how TIL therapy is evolving. From identifying eligible patients and surgical harvesting of TILs to cell expansion and reinfusion, Dr. Mahuron breaks down the entire process of TIL therapy, highlighting how her cross-disciplinary team is working to improve patient outcomes, reduce toxicity, and eventually expand treatment beyond melanoma.

They also explore the next generation of TILs f, and how oncolytic viruses and modified immune environments might bring TILs to more resistant cancers such as pancreatic and colorectal tumors.

Learn how surgical precision, immunotherapy, and translational research come together to push the boundaries of what's possible in cancer treatment. . Tune in to the full conversation now.

Click for Source